Market Closed - Nasdaq Copenhagen 08:50:00 23/07/2024 pm IST 5-day change 1st Jan Change
1,910.00 DKK +1.49% Intraday chart for Genmab A/S +4.49% -11.37%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Genmab A/S Announces DARZALEX Sales Results for the Second Quarter of 2024 CI
Genmab, J&J Log Higher Q2 Sales for Blood Cancer Drug Darzalex MT
RBC Capital Upgrades Genmab to Outperform MT
GENMAB : RBC raises its recommendation CF
RBC Upgrades Genmab to Outperform From Sector Perform, Keeps Price Target at DKK2,400 MT
Markets Powered by Alternating Current Our Logo
Myricx Pharma Ltd announced that it has received £90 million in funding from a group of investors CI
Myricx Bio announced that it has received £90 million in funding from a group of investors CI
Would you like some more inflation? Our Logo
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment MT
Genmab A/S Announces Epcoritamab Receives Positive CHMP Opinion for Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma CI
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma CI
Genmab Closes DKK3.5 Billion Share Buyback Early MT
BTIG Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating MT
Genmab Gets FDA Approval for Follicular Lymphoma Treatment MT
Genmab Wins US Approval for Follicular Lymphoma Treatment MT
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma CI
AbbVie Gets New FDA Accelerated Approval for Epkinly DJ
Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating MT
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study MT
Transcript : Genmab A/S - Special Call
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin CI
Chart Genmab A/S
More charts
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
Employees
2,286
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,882.00DKK
Average target price
2,454.35DKK
Spread / Average Target
+30.41%
Consensus
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. News Genmab A/S
  5. Genmab: A good start to 2024; guidance unchanged